vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2019-4-129-133vtio-1113Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSМодификация кислотного иона в составе диализирующей жидкостиAcid ion modification in a dialysis fluidПозЯ. Л.PozI. L.

Москва

Moscow

СтроковА. Г.StrokovA. G.

Строков Александр Григорьевич

123182, Москва, ул. Щукинская, д. 1.Тел. (499) 158-22-33 

Strokov Alexander Grigor’evich

1, Shchukinskaya str., Moscow, 123182.Tel. (499) 158-22-33

medick@bk.ruФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian Federation201902022020214129133Copyright © Поз Я.Л., Строков А.Г., 20202020Поз Я.Л., Строков А.Г.Poz I.L., Strokov A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1113

Диализирующая жидкость (ДЖ) помимо основных электролитов – натрия, калия, кальция и магния содержит буфер, необходимый для коррекции ацидоза. С целью предупреждения преципитации солей кальция и магния в ДЖ добавляется небольшое количество кислоты. В течение многих лет для этой цели использовалась уксусная кислота. Согласно данным ряда исследований, ион ацетата даже в небольшой концентрации может вызывать ряд нежелательных явлений. Это артериальная гипотензия, выработка провоспалительных цитокинов и др. Целью данного обзора литературы является рассмотрение альтернативных кислотных компонентов ДЖ, таких как лимонная, соляная, янтарная кислоты, их преимуществ, возможности и особенностей применения в широкой клинической практике.

Apart from its main electrolytes – sodium, potassium, calcium and magnesium – a dialysis fluid (DF) contains a buffer for correction of acidosis. A small amount of acid is added to the DF to prevent calcium and magnesium precipitation. Acetic acid has traditionally been used for this purpose. Several studies have shown that acetate ion, even in small concentrations, can cause a number of adverse events, such as low blood pressure, production of proinflammatory cytokines, etc. This literature review aims at considering alternative acidic components of DF, such as citric, hydrochloric, and succinic acids, as well as their advantages, possibilities and features of their use in wide clinical practice.

диализирующая жидкостьацетатцитратгидрохлоридсукцинатdialysis fluidacetatecitratehydrochloridesuccinateReferencesBolasco P, Panichi V, Paletti S, Mancini E. Will there be acetate in dialysis solutions for the foreseeable future? [Article in Italian] G Ital Nefrol. 2011; 28 (4): 359–368.Bolasco P, Panichi V, Paletti S, Mancini E. Will there be acetate in dialysis solutions for the foreseeable future? [Article in Italian] G Ital Nefrol. 2011; 28 (4): 359–368.Unarokov ZM, Mukhoedova TV, Shuvaeva OV. Comparison of sustained low-efficiency dialysis with acetate-free and acetate-containing bicarbonate dialysate in unstable patients. Artif Organs. 2014; 38 (10): 883–888. doi: 10.1111/aor.12251.Unarokov ZM, Mukhoedova TV, Shuvaeva OV. Comparison of sustained low-efficiency dialysis with acetate-free and acetate-containing bicarbonate dialysate in unstable patients. Artif Organs. 2014; 38 (10): 883–888. doi: 10.1111/aor.12251.Pizzarelli F, Cerrai T, Dattolo P, Ferro G. On-line haemodiafiltration with and without acetate. Nephrol Dial Transplant. 2006; 21 (6): 1648–1651. doi: 10.1093/ndt/gfk093.Pizzarelli F, Cerrai T, Dattolo P, Ferro G. On-line haemodiafiltration with and without acetate. Nephrol Dial Transplant. 2006; 21 (6): 1648–1651. doi: 10.1093/ndt/gfk093.Mercadal L, Franck JE, Metzger M, Yuan W, Kolko A, Monnet E et al. Improved survival associated with acetate-free haemodialysis in elderly: a registry-based study. Nephrol Dial Transplant. 2015; 30 (9): 1560–1568. doi: 10.1093/ndt/gfv248.Mercadal L, Franck JE, Metzger M, Yuan W, Kolko A, Monnet E et al. Improved survival associated with acetate-free haemodialysis in elderly: a registry-based study. Nephrol Dial Transplant. 2015; 30 (9): 1560–1568. doi: 10.1093/ndt/gfv248.Schultheiß C, Saugel B, Phillip V, Thies P, Noe S, Mayr U et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012; 16 (4): R162. doi: 10.1186/cc11485.Schultheiß C, Saugel B, Phillip V, Thies P, Noe S, Mayr U et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012; 16 (4): R162. doi: 10.1186/cc11485.Klingele M, Stadler T, Fliser D, Speer T, Groesdonk HV, Raddatz A. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care. 2017; 21 (1): 294. doi: 10.1186/s13054-017-1870-3.Klingele M, Stadler T, Fliser D, Speer T, Groesdonk HV, Raddatz A. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care. 2017; 21 (1): 294. doi: 10.1186/s13054-017-1870-3.Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PloS One. 2017; 12 (8): e0182134. doi: 10.1371/journal.pone.0182134.Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PloS One. 2017; 12 (8): e0182134. doi: 10.1371/journal.pone.0182134.Oöpik V, Saaremets I, Medijainen L, Karelson K, Janson T, Timpmann S. Effects of sodium citrate ingestion before exercise on endurance performance in well trained college runners. Br J Sports Med. 2003; 37 (6): 485–489. doi: 10.1136/bjsm.37.6.485Oöpik V, Saaremets I, Medijainen L, Karelson K, Janson T, Timpmann S. Effects of sodium citrate ingestion before exercise on endurance performance in well trained college runners. Br J Sports Med. 2003; 37 (6): 485–489. doi: 10.1136/bjsm.37.6.485Huang S, Sandholm K, Jonsson N, Nilsson A, Wieslander A, Grundström G et al. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2015; 8 (1): 31–37. doi: 10.1093/ckj/sfu127.Huang S, Sandholm K, Jonsson N, Nilsson A, Wieslander A, Grundström G et al. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2015; 8 (1): 31–37. doi: 10.1093/ckj/sfu127.Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14 (10): 429–440. doi: 10.1016/j.molmed.2008.08.001.Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14 (10): 429–440. doi: 10.1016/j.molmed.2008.08.001.Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007; 44 (1–3): 82–94. doi: 10.1016/j.molimm.2006.06.020.Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007; 44 (1–3): 82–94. doi: 10.1016/j.molimm.2006.06.020.Masuda A, Hagiwara S, Tanimoto M, Kodama F, Okumura K, Nohara N et al. Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients. Nephron Extra. 2012; 2(1): 256–268. doi: 10.1159/000342258.Masuda A, Hagiwara S, Tanimoto M, Kodama F, Okumura K, Nohara N et al. Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients. Nephron Extra. 2012; 2(1): 256–268. doi: 10.1159/000342258.Bryland A, Wieslander A, Carlsson O, Hellmark T, Godaly G. Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diab Vasc Dis Res. 2012; 9 (1): 42–51. doi: 10.1177/1479164111424297.Bryland A, Wieslander A, Carlsson O, Hellmark T, Godaly G. Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diab Vasc Dis Res. 2012; 9 (1): 42–51. doi: 10.1177/1479164111424297.Paim BA, Velho JA, Castilho RF, Oliveira HCF, Vercesi AE. Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADPlinked substrates and is partially reversed by citrate replacement. Free Radic Biol Med. 2008; 44 (3): 444–51. doi: 0.1016/j.freeradbiomed.2007.10.005Paim BA, Velho JA, Castilho RF, Oliveira HCF, Vercesi AE. Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADPlinked substrates and is partially reversed by citrate replacement. Free Radic Biol Med. 2008; 44 (3): 444–51. doi: 0.1016/j.freeradbiomed.2007.10.005Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A. et. al. Effects of citrate acid concentrate (Citrasate ® ) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012; 33 (1–3): 199–204. doi: 10.1159/000334157.Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A. et. al. Effects of citrate acid concentrate (Citrasate ® ) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif. 2012; 33 (1–3): 199–204. doi: 10.1159/000334157.Cheng YL, Yu AW, Tsang KY, Shah DH, Kjellstrand CM, Wong SM et al. Anticoagulation during haemodialysis using a citrate-enriched dialysate: a feasibility study. Nephrol Dial Transplant. 2011; 26 (2): 641–646. doi: 10.1093/ndt/gfq396.Cheng YL, Yu AW, Tsang KY, Shah DH, Kjellstrand CM, Wong SM et al. Anticoagulation during haemodialysis using a citrate-enriched dialysate: a feasibility study. Nephrol Dial Transplant. 2011; 26 (2): 641–646. doi: 10.1093/ndt/gfq396.Aniort J, Petitclerc T, Créput C. Safe use of citric acidbased dialysate and heparin removal in postdilution online hemodiafiltration. Blood Purif. 2012; 34 (3–4): 336–343. doi: 10.1159/000345342.Aniort J, Petitclerc T, Créput C. Safe use of citric acidbased dialysate and heparin removal in postdilution online hemodiafiltration. Blood Purif. 2012; 34 (3–4): 336–343. doi: 10.1159/000345342.Panichi V, Fiaccadori E, Rosati A, Fanelli R, Bernabini G, Scatena A, Pizzarelli F. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. Scientific World Journal. 2013: 703612. doi: 10.1155/2013/703612.Panichi V, Fiaccadori E, Rosati A, Fanelli R, Bernabini G, Scatena A, Pizzarelli F. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. Scientific World Journal. 2013: 703612. doi: 10.1155/2013/703612.Molina Nuñez M, de Alarcón R, Roca S, Álvarez G, Ros MS, Jimeno C et al. Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective crossover study. Blood Purif. 2015; 39 (1–3): 181–187. doi: 10.1159/000371569.Molina Nuñez M, de Alarcón R, Roca S, Álvarez G, Ros MS, Jimeno C et al. Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective crossover study. Blood Purif. 2015; 39 (1–3): 181–187. doi: 10.1159/000371569.Kuragano T, Kida A, Furuta M, Yahiro M, Kitamura R, Otaki Y et al. Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs. 2012; 36 (3): 282–290. doi: 10.1111/j.1525-1594.2011.01349.x.Kuragano T, Kida A, Furuta M, Yahiro M, Kitamura R, Otaki Y et al. Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs. 2012; 36 (3): 282–290. doi: 10.1111/j.1525-1594.2011.01349.x.Schmitz M, Loke O, Fach B, Kalb K, Heering PJ, Meinke D et al. Effects of citrate dialysate in chronic dialysis: a multicentre randomized crossover study. Nephrol Dial Transplant. 2016; 31 (8): 1327–1334. doi: 10.1093/ndt/gfv347.Schmitz M, Loke O, Fach B, Kalb K, Heering PJ, Meinke D et al. Effects of citrate dialysate in chronic dialysis: a multicentre randomized crossover study. Nephrol Dial Transplant. 2016; 31 (8): 1327–1334. doi: 10.1093/ndt/gfv347.Grundström G, Christensson A, Alquist M, Nilsson LG, Segelmark M. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol. 2013; 14: 216. doi: 10.1186/1471-2369-14-216.Grundström G, Christensson A, Alquist M, Nilsson LG, Segelmark M. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol. 2013; 14: 216. doi: 10.1186/1471-2369-14-216.Ortiz Pde S, Ramón MA, Pérez-García R, Prats EC, Cobo PA, Arroyo RA et al. Acute effect of citrate bath on postdialysis alkalaemia. Nefrologia. 2015; 35 (2): 164–171. doi: 10.1016/j.nefro.2014.10.001.Ortiz Pde S, Ramón MA, Pérez-García R, Prats EC, Cobo PA, Arroyo RA et al. Acute effect of citrate bath on postdialysis alkalaemia. Nefrologia. 2015; 35 (2): 164–171. doi: 10.1016/j.nefro.2014.10.001.Смирнов АВ, Голубев РВ, Васильев АН, Земченков АЮ, Старосельский КГ. Гемодинамические эффекты содержащего сукцинат диализирующего раствора. Тер. архив. 2015; 87 (6): 56–61. doi: 10.17116/terarkh201587656-61.Смирнов АВ, Голубев РВ, Васильев АН, Земченков АЮ, Старосельский КГ. Гемодинамические эффекты содержащего сукцинат диализирующего раствора. Тер. архив. 2015; 87 (6): 56–61. doi: 10.17116/terarkh201587656-61.

The authors declare that there are no conflicts of interest present.